Complete hematological response of CML to BRAF/MEK inhibition in a patient with metastatic melanoma

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Targeted MEK inhibition holds promise in BRAF V600E mutation-positive malignant melanoma, where cell growth through the MAP kinase (MAPK) pathway is well established. MAPK pathway activation is also important in chronic myeloid leukemia (CML) leukemogenesis. This case report suggests further evaluation of the MAPK targeting approach is warranted to extend therapeutic options in CML.

 Background

  • A case of complete hematological response of CML to MEK inhibition observed in a patient with synchronous metastatic melanoma, who received treatment with combination BRAF and MEK1/2 inhibitors

 Method

  • Study of effects of these agents on proliferation and outgrowth of myeloid precursors
  • Study of...